Information ⬇
- A major breakthrough in the understanding of opioid pharmacology came from a series of discoveries of opioid receptors, endogenous opioid peptides, their encoding genes, and endogenous opioid alkaloids.
- The endogenous opioid system is composed of a family of structurally related endogenous peptides that act at a four-member opioid receptor family consisting of the µ-opioid receptor (MOR), κ-opioid receptor (KOR), δ-opioid receptor (DOR), and orphanin FQ/nociception (NOP) receptor.
- At least three MOR subtypes have been described: µ
1 is predominantly involved in opioid analgesia, µ
2 is involved in opioid-induced respiratory depression, and µ
3 is involved in opioid-induced immune suppression.
- Functional validation of most opioid receptor subtypes awaits the development of antagonists with sufficient selectivity to allow a clear differentiation by effect.
- The endogenous opioid peptides include endorphins, enkephalins, and dynorphins, each of which display different affinities for the µ-, κ-, and δ-opioid receptors. β-endorphins have a high affinity for the µ-opioid receptor, met- and leu-enkephalins for the κ-opioid receptor, and dynorphin A for the δ-opioid receptor.
- Opioids act not only through central and peripheral neuronal pathways but also via nonneuronal mechanisms, such as actions on the immune system. Opioid receptors are linked to G proteins in the cell membrane and hence are members of the large G-proteincoupled receptor (GPCR) family. GPCRs mediate a cascade of downstream signaling pathways.
Outline ⬆